Skip to main content

7 Result(s)

within Alexei F Kisselev Remove this filter

and

  1. Article

    Open Access

    NEIL3-mediated proteasomal degradation facilitates the repair of cisplatin-induced DNA damage in human cells

    Anti-neoplastic effect of DNA cross-linking agents such as cisplatin, mitomycin C, and psoralen is attributed to their ability to induce DNA interstrand cross-links (ICLs), which block replication, transcripti...

    Umit Aliyaskarova, Yeldar Baiken, Flore Renaud, Sophie Couve… in Scientific Reports (2023)

    Download PDF (4291 KB) View Article

  2. Article

    Open Access

    A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax

    Proteasome inhibitors bortezomib and carfilzomib are the backbones of treatments of multiple myeloma, which remains incurable despite many recent advances. With many patients relapsing despite high initial res...

    Sondra L. Downey-Kopyscinski, Sriraja Srinivasa, Alexei F. Kisselev in Scientific Reports (2022)

    Download PDF (2784 KB) View Article

  3. Article

    Open Access

    Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

    Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the treatment of acute lymphoblastic leu...

    Tyler W. Jenkins, Sondra L. Downey-Kopyscinski, Jennifer L. Fields… in Scientific Reports (2021)

    Download PDF (1572 KB) View Article

  4. Article

    Open Access

    The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

    Proteasome-inhibiting drugs (PI) are gaining importance in hematologic oncology. The proteasome carries three proteolytically active subunits (β1, β2, β5). All established PI (bortezomib and carfilzomib), as ...

    Johannes Kraus, Marianne Kraus, Nora Liu… in Cancer Chemotherapy and Pharmacology (2015)

    Download PDF (2686 KB) View Article

  5. No Access

    Article

    LPS-Induced Formation of Immunoproteasomes: TNF-α and Nitric Oxide Production are Regulated by Altered Composition of Proteasome-Active Sites

    Stimulation of mouse macrophages with LPS leads to tumor necrosis factor (TNF-α) secretion and nitric oxide (NO) release at different times through independent signaling pathways. While the precise regulatory ...

    Julia Reis, **u Qin Guan, Alexei F. Kisselev… in Cell Biochemistry and Biophysics (2011)

  6. No Access

    Article

    A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway

    Abrogation of ubiquitin/proteasome-dependent turnover of p53 is critical for its activation. UbL-UBA proteins, including human homolog of Rad23 (hHR23) proteins, may regulate proteasomal degradation of substra...

    Chrystelle Brignone, Kathleen E Bradley, Alexei F Kisselev, Steven R Grossman in Oncogene (2004)

  7. No Access

    Article

    Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors

    Alfred L. Goldberg, Tatos N. Akopian, Alexei F. Kisselev… in Molecular Biology Reports (1997)